CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.

Neurol Neuroimmunol Neuroinflamm · 2015 · PMC4309527 · PMID 25635261

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

did not reach statistical significancep = 0.073so close (0.05 < p ≤ 0.1)

There was a trend for lower baseline CD56 bright NK cell counts with older age, but it did not reach statistical significance ( p = 0.073).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.